Charts
From 02/05/2022 our Markets Data content will no longer be free to read. To continue to get full access, subscribe now and receive 25% off.
Equities

Chia Tai Enterprises International Ltd

Chia Tai Enterprises International Ltd

Actions
  • Price (HKD)1.42
  • Today's Change-0.07 / -4.70%
  • Shares traded170.50k
  • 1 Year change+12.70%
  • Beta--
Data delayed at least 15 minutes, as of Nov 01 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Chia Tai Enterprises International Limited is an investment holding company principally engaged in the manufacture and sale of chlortetracycline. The Company operates its business through two segments. The Biochemical segment is engaged in the manufacture and sale of chlortetracycline products. The Industrial segment is engaged in the trading of machinery and the manufacture and sale of automotive parts.

  • Revenue in HKD (TTM)1.55bn
  • Net income in HKD19.34m
  • Incorporated1987
  • Employees900.00
  • Location
    Chia Tai Enterprises International Ltd21/F,Far East Finance Centre, 16 Harcourt Ro Hong KongHKG
  • Phone+852 25201601
  • Websitehttp://www.ctei.com.hk/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.